Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A deep dive into the LEADER trial's randomization, blinding, endpoint adjudication, statistical design, and how each methodological choice shapes interpretation of liraglutide's 13% MACE reduction in type 2 diabetes.
Read clinical reviewDeep-dive into post-trial follow-up from the LEADER cardiovascular outcomes trial of liraglutide in type 2 diabetes, covering durability of MACE reduction, late safety signals, and long-term clinical implications.
Read clinical reviewA detailed breakdown of the LEADER trial's primary MACE endpoint, secondary outcomes, time-course analysis, and subgroup responses for liraglutide in type 2 diabetes with high cardiovascular risk.
Read clinical reviewA detailed breakdown of the LEADER trial's pre-specified and post-hoc subgroup analyses, examining how liraglutide's cardiovascular benefit varied by age, sex, BMI, baseline biomarkers, and race/ethnicity in patients with type 2 diabetes.
Read clinical reviewHealth-economic analyses from the LEADER trial examined whether liraglutide's 13% MACE reduction in high-risk type 2 diabetes justifies its cost per QALY gained, with implications for payer coverage and patient decision-making.
Read clinical reviewHow the LEADER trial's 13% MACE reduction with liraglutide reshaped guideline recommendations, prescribing hierarchies, and GLP-1 receptor agonist use in type 2 diabetes with cardiovascular risk.
Read clinical review